|

Symptoms, Respiratory Dysfunction and Frailty Level in Allergic and Eosonophilic Asthmatics

RECRUITINGSponsored by Hacettepe University
Actively Recruiting
SponsorHacettepe University
Started2024-08-01
Est. completion2026-10-30
Eligibility
Age35 Years – 75 Years
Healthy vol.Accepted

Summary

The aim of this study is to determine the level of respiratory dysfunction, symptoms and frailty in patients with asthma according to different endophenotypes (allergic and eosonophilic asthma). In the light of the data obtained, it is thought that rehabilitation approaches that can be determined according to different endophenotypes in line with the evaluated parameters will guide health professionals working in this field. Hypotheses H0: There is no difference between allergic and eosonophilic asthmatics in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life. H1: There is a difference between individuals with allergic and eosonophilic asthma in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life.

Eligibility

Age: 35 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age between 35-75 years,
* Diagnosed with allergic or eosonophilic asthma according to the Global Strategy for the Prevention and Treatment of Asthma (GINA).

Exclusion Criteria:

* Known cognitive impairment,
* Having had an acute asthma attack in the last 6 weeks,
* Having changed medication in the last 4 weeks.

Conditions3

AsthmaFragilityRespiratory Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.